Literature DB >> 28255730

Medial temporal lobe epilepsy associated with hippocampal sclerosis is a distinctive syndrome.

Young Joo No1, Chiara Zavanone1, Franck Bielle2,3,4, Vi-Huong Nguyen-Michel5, Yves Samson6,3,4, Claude Adam3,7, Vincent Navarro5,3,4,7, Sophie Dupont8,9,10,11,12.   

Abstract

Epileptic syndromes are distinctive disorders with specific features, which when taken together, permit a specific diagnosis. There is actually a debate on that medial temporal lobe epilepsy with hippocampal sclerosis is an epileptic syndrome. To address this issue, we searched for discriminative semiological features between temporal lobe epilepsy patients with hippocampal sclerosis (TLE-HS patients or group 1), TLE patients with medial structural lesion other than hippocampal sclerosis or in MRI-negative cases with medial onset on further investigations (group 2) and lateral TLE patients (LTLE or group 3). We retrospectively collected data from medical and EEG-video records of 523 TLE patients, referred for surgery to the Pitié-Salpêtrière Epileptology Unit between 1991 and 2014. We identified 389 patients belonging to group 1, 61 patients belonging to group 2, and 73 patients belonging to group 3 and performed a comparative analysis of their clinical data and surgical outcomes. TLE-HS patients (group 1): (1) began epilepsy earlier (11 ± 9 vs. 20 ± 10 vs. 15 ± 9 years); (2) exhibited more frequently early febrile convulsions (FC) (59 vs 7 vs 5%); (3) presented more: ictal gestural automatisms (90 vs 54 vs 67%), dystonic posturing (47 vs 20 vs 23%), and secondary generalized tonic-clonic seizures (GTCS) (70 vs 44% vs 48%) as compared to both groups 2 and 3 patients (all p < 0.001). With respect to auras, abdominal visceral auras were more reported by TLE-HS than by LTLE patients (49 vs 16%). Three cardinal criteria correctly classified 94% of patients into TLE-HS group: history of FC, dystonic posturing, and secondary GTCS. Postoperative outcome was significantly better in TLE-HS group than in the two other groups (p = 0.03 and 0.003). Our study demonstrates that cardinal criteria are reliably helpful to distinguish patients with TLE-HS from those with other TLE and may allow considering TLE-HS as a distinctive syndrome.

Entities:  

Keywords:  Hippocampal sclerosis; Lateral lobe epilepsy; Medial temporal lobe epilepsy; Syndrome

Mesh:

Year:  2017        PMID: 28255730     DOI: 10.1007/s00415-017-8441-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Secondarily generalized seizures in temporal lobe epilepsy.

Authors:  Beata Bone; András Fogarasi; Reinhard Schulz; Csilla Gyimesi; Zsuzsanna Kalmar; Norbert Kovacs; Alois Ebner; Jozsef Janszky
Journal:  Epilepsia       Date:  2012-03-16       Impact factor: 5.864

2.  Clinical and electrographic manifestations of lesional neocortical temporal lobe epilepsy.

Authors:  N Foldvary; N Lee; G Thwaites; E Mascha; J Hammel; H Kim; A H Friedman; R A Radtke
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

3.  Lateralizing value of semiology in medial temporal lobe epilepsy.

Authors:  S Dupont; Y Samson; V-H Nguyen-Michel; C Zavanone; V Navarro; M Baulac; C Adam
Journal:  Acta Neurol Scand       Date:  2015-04-09       Impact factor: 3.209

4.  Association of ipsilateral motor automatisms and contralateral dystonic posturing: a clinical feature differentiating medial from neocortical temporal lobe epilepsy.

Authors:  S Dupont; F Semah; P Boon; J M Saint-Hilaire; C Adam; D Broglin; M Baulac
Journal:  Arch Neurol       Date:  1999-08

5.  Are auras a reliable clinical indicator in medial temporal lobe epilepsy with hippocampal sclerosis?

Authors:  S Dupont; Y Samson; V-H Nguyen-Michel; C Zavanone; S Clémenceau; R Miles; M Baulac; C Adam
Journal:  Eur J Neurol       Date:  2015-06-13       Impact factor: 6.089

6.  Mesial temporal lobe epilepsy with hippocampal sclerosis is a network disorder with altered cortical hubs.

Authors:  Seung-Hyun Jin; Woorim Jeong; Chun Kee Chung
Journal:  Epilepsia       Date:  2015-03-23       Impact factor: 5.864

7.  Seizure semiology: its value and limitations in localizing the epileptogenic zone.

Authors:  Krikor Tufenkjian; Hans O Lüders
Journal:  J Clin Neurol       Date:  2012-12-21       Impact factor: 3.077

8.  Comparison of mesial versus neocortical onset temporal lobe seizures: neurodiagnostic findings and surgical outcome.

Authors:  R S Burgerman; M R Sperling; J A French; A J Saykin; M J O'Connor
Journal:  Epilepsia       Date:  1995-07       Impact factor: 5.864

9.  ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis.

Authors:  Heinz-Gregor Wieser
Journal:  Epilepsia       Date:  2004-06       Impact factor: 5.864

10.  Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination.

Authors:  J A French; P D Williamson; V M Thadani; T M Darcey; R H Mattson; S S Spencer; D D Spencer
Journal:  Ann Neurol       Date:  1993-12       Impact factor: 10.422

View more
  3 in total

1.  Parahippocampal Involvement in Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis: A Proof of Concept from Memory-Guided Saccades.

Authors:  Silvia Colnaghi; Giorgio Beltrami; Guy Poloni; Anna Pichiecchio; Stefano Bastianello; Carlo Andrea Galimberti; Maurizio Versino
Journal:  Front Neurol       Date:  2017-11-07       Impact factor: 4.003

2.  Hubs disruption in mesial temporal lobe epilepsy. A resting-state fMRI study on a language-and-memory network.

Authors:  Elise Roger; Cedric Pichat; Laurent Torlay; Olivier David; Felix Renard; Sonja Banjac; Arnaud Attyé; Lorella Minotti; Laurent Lamalle; Philippe Kahane; Monica Baciu
Journal:  Hum Brain Mapp       Date:  2019-11-13       Impact factor: 5.038

3.  Seizure semiology in temporal lobe vs. temporal plus epilepsy using intracranial EEG monitoring.

Authors:  Abeer Khoja; Omnyah Albaradei; Ashwaq Alsulami; Mohamed Alkhaja; Mohammad Alsumaili; Ohood Khoja; Alya Khoja; Mashael Al-Khateeb
Journal:  Neurosciences (Riyadh)       Date:  2021-07       Impact factor: 0.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.